Relay Therapeutics

Historical price data

Relay Therapeutics is redefining drug discovery by focusing on the dynamic nature of proteins, moving beyond static structures to understand how protein motion influences function and disease. Its proprietary Dynamo platform combines computational structural biology, machine learning, and experimental techniques to identify novel drug targets and allosteric sites. The company has advanced a pipeline of precision oncology candidates, most notably RLY-4008, a highly selective FGFR2 inhibitor, and is building a robust portfolio targeting validated oncogenes with next-generation specificity. Relay's approach aims to create best-in-class therapies with improved safety and efficacy profiles.

The Dynamo platform integrates computational simulation, structural biology, and machine learning to visualize and drug protein motion, identifying novel allosteric binding sites to create highly selective small molecule therapies.

4 drugs in pipeline, 1 in Phase 3

Total raised: $980M

Relay competes with large pharma (e.g., Novartis, Incyte, J&J) and biotechs in the FGFR and PI3K inhibitor spaces, where its differentiation is based on superior selectivity from targeting protein motion. Its platform also faces competition from other computational drug discovery companies, though Relay's specific focus on integrating dynamic simulation with experimental validation is a key distinction.